Odyssey Health, Inc. 8-K

What Happened
Odyssey Health, Inc. announced in an 8-K filed April 24, 2026 that it closed the Master Technology and Sub-license Agreement with NeuRX Health, Inc. The agreement, originally entered on October 14, 2025 and described in Odyssey’s October 17, 2025 8-K, grants Odyssey’s wholly owned subsidiary, Odyssey Medical Devices, Inc., exclusive worldwide marketing and distribution rights to BreastCheckTM, a non-invasive test for breast abnormalities. The closing occurred on April 21, 2026 and was effected by Amendment No. 1 dated April 21, 2026.

Key Details

• Agreement dates: original Master Technology and Sub-license Agreement signed October 14, 2025; closing and Amendment No. 1 executed April 21, 2026.
• Rights granted: exclusive, worldwide marketing and distribution rights to the BreastCheckTM test to Odyssey Medical Devices, Inc.
• Closing conditions: transaction was subject to customary closing conditions for both parties, which were satisfied.
• Communications: Odyssey issued a press release announcing the closing on April 22, 2026 (Exhibit 99.1 to the 8-K). The October 17, 2025 8-K contains the full agreement form incorporated by reference.

Why It Matters
This filing documents a completed licensing and distribution deal that gives Odyssey a global commercial pathway for the BreastCheck test through its subsidiary. For investors, the agreement, now closed, could affect Odyssey’s product offerings and future revenue opportunities if the company commercializes BreastCheck successfully. The 8-K does not disclose financial terms or projected revenue; investors should look to future filings or company reports for financial impact and commercialization milestones.